Telomir Pharmaceuticals, Inc.
TELO
$1.45
-$0.05-3.33%
NASDAQ
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Net Income | -16.08M | -12.46M | -16.53M | -22.96M | -18.74M |
Total Depreciation and Amortization | -- | -- | -- | -- | -- |
Total Amortization of Deferred Charges | 0.00 | 0.00 | 4.34M | 5.08M | 5.83M |
Total Other Non-Cash Items | 13.04M | 8.37M | 7.00M | 12.28M | 7.49M |
Change in Net Operating Assets | -126.40K | 90.80K | 126.40K | 48.90K | -1.12M |
Cash from Operations | -3.17M | -3.99M | -5.07M | -5.55M | -6.55M |
Capital Expenditure | -- | -- | -- | -- | -- |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | -- | -- | -- | -- | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | -- | -- | -- | -- | -- |
Cash from Investing | -- | -- | -- | -- | -- |
Total Debt Issued | -132.40K | 0.00 | 0.00 | 1.07M | 2.76M |
Total Debt Repaid | -433.90K | -433.90K | -534.90K | -404.90K | -101.00K |
Issuance of Common Stock | 2.09M | 1.04M | 6.87M | 5.92M | 5.92M |
Repurchase of Common Stock | -- | -- | -- | -- | -- |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | 519.50K | 519.50K | 0.00 | -200.40K | -160.10K |
Cash from Financing | 2.04M | 1.12M | 6.34M | 6.38M | 8.42M |
Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | -1.13M | -2.87M | 1.26M | 832.20K | 1.87M |